This review summarizes the pathology, risk factors, and current guidelines for managing venous thromboembolism in cancer patients.
Answers are grounded in this paper and cite their sources.
Summarizes current VTE management in cancer for clinicians; leaves open need for updated RCTs on emerging therapies.
Thrombosis and thromboembolic events contribute to significant morbidity in cancer patients. Venous thrombosis embolism (which includes deep vein thrombosis and pulmonary embolism) accounts for a large percentage of thromboembolic events. Appropriate identification of cancer patients at high risk for venous thromboembolism and management of thromboembolic event is crucial in improving the quality of care for cancer patients. However, thromboembolism in cancer patients is a complex problem and the management has to be tailored to each individual. The focus of this review is to understand the complex pathology, physiology and risk factors that drive the process of venous thrombosis and embolism in cancer patients and the current guidelines in management.
No takes yet. Share an insight, caveat, or question.
Tukaye et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: